PDS Biotechnology Corporation (PDSB) financial statements (2021 and earlier)

Company profile

Business Address 25B VREELAND ROAD
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29331721121722
Cash and cash equivalents29331721121722
Other undisclosed current assets1033211
Total current assets:30341924141823
Noncurrent Assets
Operating lease, right-of-use asset111   1
Property, plant and equipment0000000
Intangible assets, net (including goodwill)    311
Intangible assets, net (excluding goodwill)    311
Other noncurrent assets      0
Other undisclosed noncurrent assets    (3)  
Total noncurrent assets:1110013
TOTAL ASSETS:31342024141926
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3324232
Accounts payable1213112
Accrued liabilities2111111
Debt      0
Restructuring reserve  00011
Other undisclosed current liabilities000    
Total current liabilities:3334344
Noncurrent Liabilities
Long-term debt and lease obligation011   1
Operating lease, liability011   1
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities: 11   1
Total liabilities:4444345
Stockholders' equity
Stockholders' equity attributable to parent27311720121621
Common stock0000000
Additional paid in capital71715353413939
Accumulated deficit(44)(40)(36)(33)(29)(24)(18)
Total stockholders' equity:27311720121621
Other undisclosed liabilities and equity (1)(1)  00
TOTAL LIABILITIES AND EQUITY:31342024141926

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(4)(4)(3)(4)(6)(6)(4)
Operating loss:(4)(4)(3)(4)(6)(6)(4)
Nonoperating income
(Investment Income, Nonoperating)
0000100
Interest and debt expense    (0)  
Loss from continuing operations before income taxes:(4)(4)(3)(4)(5)(6)(4)
Other undisclosed loss from continuing operations    (0)  
Net loss:(4)(4)(3)(4)(5)(6)(4)
Other undisclosed net income attributable to parent    1  
Net loss available to common stockholders, diluted:(4)(4)(3)(4)(4)(6)(4)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(4)(4)(3)(4)(5)(6)(4)
Comprehensive loss:(4)(4)(3)(4)(5)(6)(4)
Other undisclosed comprehensive income, net of tax, attributable to parent    1  
Comprehensive loss, net of tax, attributable to parent:(4)(4)(3)(4)(4)(6)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: